Thomas Walter

Mr. Thomas Walter

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 June 2015 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
PDF file
MHM Heetfeld
M Heetfeld
CCC N Chougnet
C N Chougnet
IOI H Olsen
I H Olsen
ARA Rinke
A Rinke
IBIvan Borbath
Ivan Borbath
TWThomas Walter
Thomas Walter
Data on gastroenteropancreatic neuroendocrine neoplasms (NEN) G3 (well-differentiated neuroendocrine tumors (NET G3) and neuroendocrine carcinoma (NEC)) are limited. We retrospectively study patients with NET G3 and NEC from eight European centers. Data examined included clinical and pathological characteristics at diagnosis, therapies and outcomes. Two hundred and four patients were analyzed (37 NET G3 and 167 NEC). Median age was 64 (21–89) years. Tumor origin included pancreas (32%) and colon-rectum (27%). The primary tumor was resected in 82 (40%) patients. Metastatic disease was evident at diagnosis in 88% (liver metastases: 67%). Median Ki-67 index was 70% (30% in NET G3 and 80% in NEC;P<0.001). Median overall survival (OS) for all patients was 23 (95% CI: 18–28) months and significantly higher in NET G3 (99 vs 17 months in NEC; HR=8.3;P<0.001). Platinum-etoposide first line chemotherapy was administered in 113 (68%) NEC and 12 (32%) NET G3 patients. Disease control rate and progression free survival (PFS) were significantly higher in NEC compared to NET G3 (P<0.05), whereas OS was significantly longer in NET G3 (P=0.003). Second- and third-line therapies (mainly FOLFIRI and FOLFOX) were given in 79 and 39 of NEC patients; median PFS and OS were 3.0 and 7.6 months respectively after second-line and 2.5 and 6.2 months after third-line chemotherapy. In conclusion, NET G3 and NEC are characterized by significant differences in Ki-67 index and outcomes. While platinum-based chemotherapy is effective in NEC, it seems to have limited value in NET G3.

13 January 2015 in British Journal of Cancer
Verified
Journal Article
Open access
TWThomas Walter
Thomas Walter
BBB van Brakel
B van Brakel
CVC Vercherat
C Vercherat
VHV Hervieu
V Hervieu
JFJ Forestier
J Forestier
JSJ-Y Scoazec
J-Y Scoazec
O(6)-Methylguanine-DNA methyltransferase (MGMT) loss of expression has been suggested to be predictive of response to temozolomide in neuroendocrine tumours (NETs), but so far, only limited data are available. We evaluated the prognostic and predictive value of MGMT status, assessed by two molecular methods and immunohistochemistry, in a large series of NETs of different origins. A total of 107 patients, including 53 treated by alkylants (temozolomide, dacarbazine or streptozotocin), were retrospectively studied. In each case, we used methyl-specific PCR (MS-PCR) and pyrosequencing for evaluation of promoter methylation and immunohistochemistry for evaluation of protein status. MGMT promoter methylation was detected in 12 out of 99 (12%) interpretable cases by MS-PCR and in 24 out of 99 (24%) by pyrosequencing. O(6)-Methylguanine-DNA methyltransferase loss of expression was observed in 29 out of 89 (33%) interpretable cases. Status of MGMT was not correlated with overall survival (OS) from diagnosis. Progression-free survival and OS from first alkylant use (temozolomide, dacarbazine and streptozotocin) were higher in patients with MGMT protein loss (respectively, 20.2 vs 7.6 months, P<0.001 and 105 vs 34 months, P=0.006) or MGMT promoter methylation assessed by pyrosequencing (respectively, 26.4 vs 10.8 months, P=0.002 and 77 vs 43 months, P=0.026). Our results suggest that MGMT status is associated with response to alkylant-based chemotherapy in NETs.

1 July 2017 in European Journal of Cancer
Verified
Journal Article
Closed access
TWThomas Walter
Thomas Walter
DTDavid Tougeron
David Tougeron
EBE. Baudin
E. Baudin
KMK. Le Malicot
K. Le Malicot
TLT. Lecomte
T. Lecomte
PRPhilippe Rougier
Philippe Rougier


1 June 2019 in Journal of Thoracic Oncology
Verified
Journal Article
Closed access
PRPatrick Robelin
Patrick Robelin
JHJulien Hadoux
Julien Hadoux
JFJulien Forestier
Julien Forestier
DPDavid Planchard
David Planchard
VHValérie Hervieu
Valérie Hervieu
TWThomas Walter
Thomas Walter

1 January 2013 in Journal of Vascular and Interventional Radiology
Verified
Journal Article
Closed access
TWThomas Walter
Thomas Walter
CHChia S. Ho
Chia S. Ho
AHAnne M. Horgan
Anne M. Horgan
AWAndrew Warkentin
Andrew Warkentin
SGSteve Gallinger
Steve Gallinger
JKJennifer J. Knox
Jennifer J. Knox